JayantKumarMD

Nephrology • Albuquerque, NM

Physician

Join to view full profile

Dr. Kumar is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Kumar's full profile

Already have an account?

Office
3821 Masthead St Ne
Albuquerque, NM 87109
Phone+1 505-998-7400

Fax+1 505-998-7741
Is this information wrong?

Education & Training

Stanford Health Care-Sponsored Stanford UniversityFellowship, Nephrology, 1998 - 2001
Montefiore Medical Center/Albert Einstein College of Medicine (New Rochelle)Residency, Internal Medicine, 1993 - 1994
Nassau University Medical CenterResidency, Internal Medicine, 1992 - 1992
All India Institute of Medical SciencesClass of 1990

Certifications & Licensure

CA State Medical License 1998 - Present
NM State Medical License 2007 - 2026
AR State Medical License 1995 - 2011
American Board of Internal Medicine Nephrology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2015-2022

Clinical Trials

Study to Evaluate the Efficacy, Safety and Immunogenicity of Subcutaneous HX575 in the Treatment of Anemia Associated With Chronic Kidney Disease (SWEEP) Start of enrollment: 2009 Apr 01
Withdrawn
Phase 3
Evaluate the Efficacy and Safety of Once Daily Administration of Atrasentan Tablets (Low and High) Compared to Placebo in Reducing Residual Albuminuria in Type 2 Diabetic Patients With Nephropathy Who Are Treated With the Maximum Tolerated Labeled Dose of a Renin Angiotensin System (RAS) Inhibitor Start of enrollment: 2011 Apr 01
Completed
Phase 2
Roxadustat in the Treatment of Anemia in Chronic Kidney Disease Patients Not Requiring Dialysis Start of enrollment: 2013 Sep 03
Completed
Phase 3
Roxadustat in the Treatment of Anemia in Chronic Kidney Disease (CKD) Patients, Not on Dialysis, in Comparison to Darbepoetin Alfa Start of enrollment: 2014 Mar 12
Completed
Phase 3
Study of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus Start of enrollment: 2014 Jun 01
Completed
Phase 2, Phase 3
Safety and Pharmacokinetics of IV CR845 in Hemodialysis Patients, and Its Efficacy in Patients With Uremic Pruritus Start of enrollment: 2014 Jul 01
Completed
Phase 2
Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Participants With ESRD on Stable Dialysis Start of enrollment: 2015 Jan 15
Completed
Phase 3
Efficacy and Safety of Canagliflozin (TA-7284) in Patients With Diabetic Nephropathy Start of enrollment: 2018 Feb 15
Completed
Phase 3
Study of Vadadustat in Hemodialysis Participants With Anemia Switching From Epoetin Alfa Start of enrollment: 2019 Jan 31
Completed
Phase 2
Renal Effects of Treatment With Empagliflozin Alone or in Combination With Semaglutide in Patients With Type 2 Diabetes and Albuminuria Start of enrollment: 2019 Nov 01
Not yet recruiting
Phase 4
Join now to see all

Publications & Presentations

PubMed

Long-term remission of recurrent parvovirus-B associated anemia in a renal transplant recipient induced by treatment with immunoglobulin and positive seroconversion.
Kumar J, Shaver MJ, Abul-Ezz S> ;Transplant infectious disease : an official journal of the Transplantation Society.
Cinacalcet for secondary hyperparathyroidism in hemodialysis recipients.
Ali K Owda, Muhammad G Alam, Jayant Kumar> ;The New England Journal of Medicine. 2004 Jul 8
7 citations
A Comparison of the Safety and Efficacy of HX575 (Epoetin Alfa Proposed Biosimilar) with Epoetin Alfa in Patients with End-Stage Renal Disease.
Matthew R. Weir, Pablo E. Pergola, Rajiv Agarwal, Jeffrey C. Fink, Nelson Kopyt, Jayant Kumar, Susanne Schmitt, Gregor Schaffar, Anita Rudy, James McKay, Radmila Kance...> ;American Journal of Nephrology. 2017 Oct 30
57 citations
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Nalbuphine ER Tablets for Uremic Pruritus
Vandana S Mathur, Jayant Kumar, Paul W Crawford, Howard Hait, Thomas Sciascia, Tr Study Investigators> ;American Journal of Nephrology. 2017 Jan 1
5 citations
Potential effect of zoledronate therapy in heavy proteinuria.
Neriman Gokden, Maurizio Zangari, Elici F, Bart Barlogie, Jayant Kumar> ;Clinical Nephrology. 2007 Apr 1
10 citations
Morphologic Manifestations of Combined Light-chain Deposition Disease and Light-chain Cast Nephropathy
Neriman Gokden, Neslihan Cetin, Nagihan Colakoglu, Jayant Kumar, Sameh R. Abul-Ezz, Bart Barlogie, Helen Liapis, Patrick D. Walker> ;Ultrastructural Pathology. 2007 Mar 1
Long-term outcome of renal transplantation from older donors.
Mandip Panesar, Jayant Kumar, Sameh Abul-Ezz> ;The New England Journal of Medicine. 2006 May 11
5 citations
Hepatitis B infection as a possible cause of focal segmental glomerulosclerosis (FSGS).
J. Herberth, Z. Herberth, Sameh R. Abul-Ezz, Jayant Kumar, Neriman Gokden> ;Clinical Nephrology. 2006 May 1
Membranoproliferative Injury Pattern in a Renal Allograft
Neriman Gökden, Michele Rossini, Jayant Kumar, Agnes B. Fogo> ;American Journal of Kidney Diseases. 2005 Sep 1
3 citations
Kidney disease as an independent risk factor for cardiovascular events
Jayant Kumar, Sudhir V. Shah> ;Journal of Renal Nutrition. 2005 Jan 1
110 citations
A Distinct Pathway of Cell-Mediated Apoptosis Initiated by Granulysin
Allan A. Kaspar, Satoshi Okada, Jayant Kumar, Francis R Poulain, Katerina A. Drouvalakis, Ameeta Kelekar, Dennis A. Hanson, Ruth M. Kluck, Yasumichi Hitoshi, Daniel Jo...> ;Journal of Immunology. 2001 Jul 1
35 citations
Granulysin: a novel antimicrobial.
Jayant Kumar, Satoshi Okada, Carol Clayberger, Alan M. Krensky> ;Expert Opinion on Investigational Drugs. 2001 Feb 1
Join now to see all

Press Mentions

New Mexico Medical Society Physician Shortage SummaryFebruary 19th, 2023
COVID-19 Vaccine Trial Kicking off in ABQJanuary 29th, 2021
Trevi Therapeutics’ Data to Be Presented at the American Academy of Dermatology’s 74March 1st, 2016